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Background: Colorectal cancer becomes one of the most common cancer in Indonesia. Fluorouracil is an essential drug in colorectal cancer therapy as it has been supplemented in about 69% of current regiments of chemotherapy. However, drug resistance has reduced 
its clinical applications. Many factors that contribute to fluorouracil resistance have been investigated including overexpression of Multidrug Resistance Protein 5 (MRP 5) and high level expression of Thymidylate Synthase (TS). Therefore, the expression of those proteins may become key indicators to predict the presence of resistance in the 
model of fluorouracil-resistance-WiDr colon cancer cell line. 
Objective: The aim of this study is to characterize a 5-FU acquired resistance WiDr colon cancer cell line, focus on the expression of MRP5 and TS.
Methods: This study was a post test controlled group design. The expression of MRP5 and TS were analyzed using immunocytochemistry method. Before protein expression analysis, 4 groups of WiDr colon cancer cell line, group 1, 2, 3, and 4 (control) were treated with 4 
different concentration of fluorouracil 12.3 μM, 6.15 μM, 3.08 μM, and 
0 μM respectively. Previous study showed that a significant increased 
level of IC50 value is observed in group induced with fluorouracil 3.08 
μM (group 3). Statistical tests for protein expression performed with 
SPSS version 19 using Kruskall Wallis with 95% confidence level (p 
<0.05). 
Results: The expression of MRP5 and TS in the group developed  
fluorouracil resistance (group 3) were significantly increased compared 
to control group (p<0.05). In contrast, the other group exposed with 
higher dose of fluorouracil did not show both significant increased 
level of IC50 nor significant different of MRP5 and TS expression compared with the control group.
Conclusion: The model of fluorouracil-acquired resistant WiDr cell line expresses Thymidilate Synthase and Multidrug Resistance Protein 
5. The expressions of these proteins are in accordance with the profile 
of fluorouracil resistancy.
Yolanda et al.  The expression of multidrug resistance ...
JKKI 2015;7(2):
60
Latar belakang: Kanker kolorektal merupakan 
salah satu kanker yang sering ditemui di Indonesia. 
Fluorouracil (5-FU) merupakan obat yang esensial 
dalam terapi kanker tersebut. Fluorouracil 
disuplementasikan pada sekitar 69% dari seluruh 
regimen kemoterapi yang ada saat ini. Namun obat 
ini mulai terbatas aplikasi klinisnya dikarenakan 
adanya resistensi obat. Terdapat beberapa 
faktor yang berkontribusi pada proses terjadinya 
resistensi, antara lain Multidrug Resistance Protein 
5 dan Thymydilate Synthase. Ekspresi kedua protein 
tersebut dapat menjadi indikator kunci terjadinya 
resistensi pada model sel kanker WiDr yang telah 
dibuat resisten terhadap fluorouracil. 
Tujuan: Penelitian ini bertujuan untuk mengetahui 
karakteristik model kanker kolon sel line WiDr 
resisten 5-FU terutama dalam hal ekspresi Multidrug Resistance Protein 5 dan Thymydilate 
Synthase. 
Metode: Penelitian ini merupakan posttest controlled group design. Uji imunositokimia 
dilakukan untuk melihat adanya ekspresi protein 
MRP5 dan TS. Sebelum dilakukan analisa protein, 
telah dikembangkan 4 kelompok sel line WiDr, 
yakni kelompok 1, 2, 3, dan 4 yang masing-masing 
dipapar dengan 4 konsentrasi fluorouracil 12.3 
μM, 6.15 μM, 3.08 μM, dan 0 μM. Studi sebelumnya 
menunjukkan bahwa peningkatan IC50 yang 
signifikan terjadi pada kelompok yang diberi 
paparan fluorouracil 3.08 μM (kelompok 3). Analisis 
statistic menggunakan SPSS 19. Uji statistik yang 
digunakan adalah uji Kruskall Wallis untuk analisis 
ekspresi protein dengan interval kepercayaan 95% 
(p<0.05)
Hasil: Ditemukan nilai ekspresi MRP5 dan TS yang 
meningkat secara signifikan pada kelompok sel line 
WiDr yang resisten terhadap fluorouracil (p<0.05). 
Tidak didapatkan kenaikan ekspresi MRP5 dan 
TS yang signifikan pada kelompok yang tidak 
mengalami resistensi fluorouracil
Kesimpulan: Model sel line kanker kolon WiDr yang 
resisten terhadap 5-FU mengekspresikan protein 
Thymidilate Synthase dan Multidrug Resistance Protein 5. Ekspresi protein tersebut berhubungan 
dengan profil resistensi sel terhadap fluorouracil.
INTRODUCTIONColorectal cancer becomes one of the most common cancer in Indonesia. World Health Organization has reported about 17,326 cases in men and 16,413 cases in women, causing 25,253 for total mortality.1-2 Nowadays, fluorouracil becomes an essential drug in colorectal cancer 
therapy as it has been supplemented in about 69% of current regiments chemotherapy for colon cancer3. Drug resistance has reduced its clinical applications however. Fluorouracil 
resistance has frequently existed in the treatment of digestive tract cancer.4-5Fluorouracil generates cytotoxicity by building a stable complex with thymidylate synthase (TS). This complex, thereafter, inhibits deoxythimidine monophosphate (dTMP) synthesis. The reduction of dTMPs then followed by downstream depletion of deoxythimidine triphosphate (dTTP) which  essential for DNA replication and repair.6
Many factors that contribute to fluorouracil resistance have been investigated including overexpression of Multidrug Resistance Protein 5 (MRP5/ABCC5) and high level expression of thymidylate synthase (TS).7  Multidrug Resistance Protein 5 is a family of ABC transporter and localized in the basolateral membrane of duodenum, terminal ileum, and all sites of the colon.8 Multidrug Resistance Protein 5 mediates 
the efflux of fluorouracil metabolites including 
5-FdUMP, 5-FUMP, and dUMP out from the cell, 
thus, causes 9-fold resistance to 5-FU6. The other protein, Thymidylate Synthase, is a key enzyme in DNA synthesis and becomes a target 
enzyme of 5-FU to induce inhibitory effect of DNA synthesis. Therefore, high levels of TS will also predict resistance.9To develop a new strategy against drug 
resistance, a model of fluorouracil resistance WiDr colon cancer cell line has been developed previously.10 The aim of this study is to evaluate the expression of proteins responsible for 
fluorouracil resistance, MRP5 and TS, expressed 
in that fluorouracil-resistance WiDr colon cancer model.
METHODS
MaterialsABCAM (M5II–54) rat monoclonal antibody 
anti MRP5, Starr Trek HRP-DAB (Biocare), 
primary mouse anti-TS human antibody 
(clone TS106, Zymed), DMEM medium, Fetal 
bovine serum, trypsin, penicillin-streptomisin, 
amphotericin, Complete medium (FBS 10ml + 
penicillin-streptomisin 2 ml + Amphotericine 0.5 
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ml + DMEM medium ad to 100 ml), PBS, MTT solution, Sodium dodesil sulphate. Adenocarcinoma cell line WiDr was obtained from Chemotherapy and Chemoprevention Research Centre, Faculty of Pharmacy, Gadjah 
Mada University. The models of fluorouracil-resistance WiDr colon cancer cell line had been developed previously by giving 5 intermittent 
fluorouracil exposures as described previously.10 
Briefly, before protein expression analysis, 4 groups of WiDr colon cancer cell line, group 1, 2, 3, and 4 (control) were treated with 4 
different concentration of fluorouracil 12.3 μM, 
6.15 μM, 3.08 μM, and 0 μM respectively in 5 
cycles. Previous study showed that a significant increased level of IC
50
 value is observed in group 
induced with fluorouracil 3.08 μM (group 3).10 
Cells were considered as resistance if its 5-FU IC
50
 
post exposure increases significantly compared 
with 5-FU IC
50
 of the parental cells.11Thereafter, in  this study, the expression of Multidrug Resistance Protein 5 and Thymydilate Synthase were analyzed from all of those groups of WiDr colon cancer cell line models.
Immunocytochemistry analysis of  Multidrug 
Resistance Protein 5 expressionThe MRP5 expression was analyzed using immunocytochemistry (ICC) method. Cells were considered as positive when immunological reaction is present in the membrane of the cell.  It 
was a modification from previous method.12  After 
the cultured cells were fixed in cold methanol, endogenous peroxidase blocker was added and 
the cells were incubated for 20 minutes, and then rinsed with deionized water. The slides then 
were flood with PBS wash buffer. The slide was drained before of protein blocker were added for 
5-10 minutes. After incubation, protein blocker was drained before the ABCAM (M5II–54) 
rat monoclonal antibody (1:20 dilution) was 
added and incubated 60 minutes. The slide was washed again with PBS. Afterwards, the cells 
were treated with anti-mouse antibody for 10 minutes, followed by PBS wash buffer 2 times. This procedure then was followed by addition 
of DAB chromogen/substrate 3-5 minutes at room temperature. The slides were washed again using deionized water before counterstained 
with hematoxilin for 45 minutes. The analysis was performed in duplicate. 
Statistic AnalysisAll of the statistical analyses were performed using statistical program SPSS 19. To assess the extent of MRP 5 and TS expressions in colon cell 
line WiDr resistance to 5-FU, the percentage of the positive cells in each treatment group were compared to positive cells in control group using 
Kruskall Wallis with 95% confidence level (p 
<0.05). 
RESULTS
Multidrug Resistance Protein 5 ExpressionThe expression of Multidrug Resistance Protein 5 was increased in group 3 (Figure 1). From the statistical analysis, we found that the increased level of MRP5 in group 3 was 
statistically significant compared to group 4 
(control group) (p<0.05) (Table 1). In contrast, the other groups that were not developed 
fluorouracil resistance did not show significant increase of MRP5 expression compared to the control group.
Figure 1  The expression of Multidrug Resistance Protein 5 in WiDr cell line of each group after various 
concentration of fluorouracil exposure. These slides 
were observed using magnification 400x. a. MRP5 expression in group 1, b. MRP5 expression in group 2, c. MRP5 expression in group 3, d. MRP5 expression in group 4 (control).
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Group [5-FU] exposure (µM) Mean percentage of MRP5 positive cells (Mean ± SD) ICC£1 12.3 0.45 ± 0.64
0.999
2 6.15 0.0 ± 0.03 3.075 31.77 ± 0.23*4 control 0.0 ± 0.0
*p<0.05, compared to control group£Intraclass correlation
Thymydilate Synthase ExpressionThe expression of Thymydilate Synthase was increased in group 2 and 3 (Figure 2). However, 
statistic analysis found that the significant increased level of Thymydilate Synthase was 
only found in group 3 (p<0.05) (Table 2). There 
was no significant increase of TS expression on the other groups that were not developed 
fluorouracil resistance.
Group [5-FU] exposure (µM) Mean percentage of MRP5 positive cells (Mean ± SD) ICC£1 12.3 0.0 ± 0.0
0.994
2 6.15 5.86 ± 0.083 3.075 67.27 ± 0.99*4 control 0.0 ± 0.0
*p<0.05, compared to control group£Intraclass correlation
DISCUSSION
Resistance to 5-FU chemotherapy is a key problem in colon cancer therapy and can be induced by several factors. The process of chemoresistance development in the tumors itself can be mediated by various cellular mechanisms including low drug concentration at the intracellular target sites and overexpression of target protein.14 
ATP-binding cassette (ABC) transporters family are known to be responsible in the 
development of resistance by the efflux of anticancer agents outside of cancer cells and causing low drug concentration at the cells.15 Multidrug Resistance Protein 5 is one of the ABC transpoters family which may reduce 
5-FU level intracellular by mediating transport 
of 5-Fluorouridine-5-Monophosphate (5-FUMP) out from the cell. One of the substance, 
5-Fluorouridine-5-Monophosphate, is a 
metabolite of 5-FU that will be converted into 
5-FUTP and leading to RNA incorporation.6 The 
decreased level of 5-FUMP lead to depletion of 
5-FUTP and finally could lead to the reduction of RNA incorporation. Moreover, the exposure of 
5-FU could induce the expression of Multidrug Resistance Protein 5.16
In this study, the significant increased of the Multidrug Resistance Protein 5 expression in 
fluorouracil-resistance WiDr cell line models indicates that MRP5 expression correlates with 
the profile of fluorouracil resistancy. The data (Table 1) showed that the expression of MRP5 
only found in group that developed fluorouracil resistance. The modulation of MRP5 expression 
Figure 2  The expression of Thymydilate Synthase in WiDr cell line of each group after various concentration 
of fluorouracil exposure. These slides were observed 
using magnification 400x a. TS expression in group 1; b. 
TS expression in group 2; c. TS expression in group 3; d. TS expression in group 4 (control).
Table 1  Mean percentage of MRP5 positive cells on WiDr cell line after various concentration of 
fluorouracil exposure.
Table 2  Mean percentage of Thymydilate Synthase (TS) positive cells on WiDr cell line after 
various concentration of fluorouracil exposure.
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using drug exposure also found in another study employing another cell line as the sample.13-14 The 
expression of MRP5 in adriamycin resistance-human cancer cell line could be induced after 1 exposure of drug to the cell.17Thymydilate Synthase is a target protein of 
fluorouracil. It plays a crucial role the process of 
DNA synthesis. The cytotoxic effect of fluorouracil is mainly generated from the inhibition of this protein. The induction of Thymydilate Synthase 
expression can be obtained by repeated 5-FU exposure. The results of this study represent that the expression of Thymydilate Synthase can 
be found only in group that develop fluorouracil 
resistance. The significant correlation between 
TS expression and the IC50 value of the cells indicates that TS contributes in the development 
of fluorouracil-acquired resistance (Table 2).This study is relevant with previous study that showed an overexpression of Thymydilate 
Synthase in 5-FU resistance cell line after 6th 
fluorouracil exposure.18 In clinical setting, the expression of Thymydilate Synthase increases 
since the first 48 hours after initial administration 
of fluorouracil.19Overall, this study suggests that the expression of Multidrug Resistance Protein 5, in accordance with Thymidilate Synthase, will be found in the 
model of fluorouracil resistance WiDr colon cancer cell line. These data support the concept 
that the mechanism of fluororuracil resistance in WiDr colon cancer line is likely related with the expression of these proteins.
CONCLUSIONS
The model of 5-FU-acquired resistant WiDr cell line expresses Thymidilate Synthase and Multidrug Resistance Protein 5 after 5 
intermitten 5-FU exposures. The profile of 
protein expression correlates with the profile 
of fluorouracil resistancy.Further study with intermittent analysis should be done to analyze the possibility of the time dependent manner of the MRP5 and TS 
expression in the fluorouracil resistance WiDr colon cancer model.
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